Lorazepam injection vials recalled for elevated impurities and degradation
Hikma Pharmaceuticals is recalling 1,352,475 vials of Lorazepam Injection due to failed quality tests showing elevated degradation compounds. Affected lots were distributed nationwide and in Puerto Rico.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II drug recall affecting a large quantity of injectable medication due to confirmed quality failure with elevated degradation products. Although no illnesses or injuries have been reported, degradation in a benzodiazepine injectable product presents a risk-of-harm to patients.
Plain-English summary
Hikma Pharmaceuticals USA Inc. is recalling Lorazepam Injection, USP, 2mg/mL vials (NDC 0641-6044-01 and -25) manufactured by West-Ward. A total of 1,352,475 vials are affected due to failed quality specifications.
During retained sample testing, out-of-specification results were found for total related compounds. Specifically, Related Compound-C was elevated beyond acceptable limits, indicating chemical degradation of the injectable product.
The affected lots (070086 and 070128, expiring July 2023) were distributed nationwide in the United States and Puerto Rico.
The recalled product
- Product
- LORAZEPAM (LORAZEPAM)
- Brand
- LORAZEPAM
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Category
- Drug — Benzodiazepine Injectable
- Affected units
- 1,352,475
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lots: 070086
- 070128
- Exp. 07/2023
Distribution
Related recalls
Same brand · LORAZEPAM
- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- HighLorazepam Tablets Recalled Due to Sub-Potency and Failed Stability Testing
FDA (Drugs) · 2025-02-26
- HighLorazepam Tablets Recalled for Failed Impurity and Potency Specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam Injection Recalled for Out-of-Specification Impurities and Degradation
FDA (Drugs) · 2022-08-17
Same manufacturer · Hikma Pharmaceuticals USA Inc.
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateAlendronate Sodium Oral Solution Recalled for Out-of-Specification Assay Results
FDA (Drugs) · 2026-05-06
- SevereFDA Recalls Acetaminophen Injection Due to Labeling Mix-up
FDA (Drugs) · 2024-08-28
- HighMorphine Sulfate Ampuls Recalled for Expired Filters in Cartons
FDA (Drugs) · 2024-03-27
- HighGanciclovir injection vials contain mislabeled cladribine vials in cartons
FDA (Drugs) · 2023-01-04
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08